NIKKEI 225
38,346.80 +72.75 (+0.19%) HANG SENG
18,095.52 +332.49 (+1.87%) CRUDE OIL
79.43 +0.43 (+0.54%) GOLD FUTURES
2,327.80 +16.80 (+0.73%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,867.19 -2,082.48 (-4.34%)
Denali Therapeutics Inc. (DNLI)
After hours:
| Previous close | 15.44 |
| Open | 15.53 |
| Bid | 16.11 x 100 |
| Ask | 16.15 x 100 |
| Day's range | 15.40 - 16.72 |
| 52-week range | 14.56 - 33.31 |
| Volume | |
| Avg. volume | 1,258,211 |
| Market cap | 2.303B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which
- GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights. "2023 was a year of significant progress across our broad thera
- GlobeNewswire
Denali Therapeutics Announces $500 million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its comm
